Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study

Eiichi TanakaInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, JapanCorrespondence[email protected]

Eisuke InoueInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Daisuke HoshiInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Yoko ShimizuInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Akiko KobayashiInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Naoki SugimotoInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Kumi ShidaraInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Eri SatoInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Yohei SetoInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Ayako NakajimaInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Shigeki MomoharaInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Atsuo TaniguchiInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Hisashi YamanakaInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Your download is now in progress and you may close this window